Liposomal formulations of polymyxin B and uses thereof
AssigneeUniversity of Houston System
InventorsVincent Tam, Diana Chow, Jie Gohlke
Life of this patent
Estimating the term…
Abstract
The present invention provides an intravenous liposomal formulation of a low dose polymyxin B or a pharmaceutical composition thereof. The present invention also provides methods utilizing the intravenous liposomal formulation or its pharmaceutical composition for increasing the therapeutic efficacy during treatment of a bacterial infection in a subject, for decreasing exposure of renal tissue to the polymyxin B during a course of polymyxin B treatment and for lowering exposure to polymyxin B in renal tissues in a subject receiving polymyxin B treatment.
Claims16
An intravenous liposomal formulation, consisting of:
- unilamellar vesicles each composed of lipid components dipalmitoylphosphatidylcholine and at least one of cholesterol, α-tocopherol, or phosphatidylserine at a vesicle size of about 714 nm to about 1372 nm;
- and
- a low dose of about 1 mg/kg to about 4 mg/kg of polymyxin B encapsulated in said vesicles at a weight ratio of polymyxin B to the lipid components of about 1:20 to about 1:2;
- for delaying onset of nephrotoxicity.
A method for delaying onset of nephrotoxicity in a subject receiving treatment with polymyxin B, comprising the step of:
- administering to the subject pharmacological amounts of an intravenous liposomal formulation of a low dose of polymyxin B or pharmaceutical composition thereof effective to delay the onset of nephrotoxicity in the subject.
Dependencies are inferred from the claim text.